This site is intended for Healthcare professionals only.

Ciprofloxacin No longer Effective In Shigellosis, Typhoid


Ciprofloxacin No longer Effective In Shigellosis, Typhoid

Hyderabad : Researchers have found that indiscriminate and irresponsible use of ciprofloxacin which used to be sufficiently capable to kill Shigella bacteria that causes severe diarrhoea and even deaths in children is no longer effective against them. It is reported that new strains of Shigella have developed resistance to the powerful antibiotic. Shigella, along with bacteria like rotavirus, E coli, Salmonella and Campylobacter, causes severe diarrhoea and dysentery in the country. They are transmitted mostly by contaminated water and food.

The random and reckless use of antibiotics has led to a fast-approaching crisis in the form of Antibiotic Resistance. Center for Disease Control and Prevention (CDC) of USA  has already issued  a warning against emerging strains of Shigella bacteria with reduced susceptibility to ciprofloxacin. “Strains of Shigella developing resistance to ciprofloxacin ,main antibiotic drug used for treatment of shigellosis is a big blow to the healthcare system.

On one hand, physicians will be left with no choice other than administering stronger antibiotics and on other hand this will lead to increased healthcare costs.It is reported that there is increased incidence of resistance to Ciprofloxacin in shigellosis in Telangana and AP this will result in increased morbidity and high mortality and loss of manpower hours.

Unfortunately, Ciprofloxacin has also become ineffective against resistant strains Salmonella typhi which is cause of Typhoid according to another Media Report. A research published in Journal of Global Infectious Di urnal of Global Infectious Diseases in 2010 by Safdarjung doctors had pre-empted the problem. Ciprofloxacin, they wrote, has become a norm for treating enteric fever or typhoid, but in future novel molecular substitutions (new antibiotics) may become frequent owing to irrational use of ciprofloxacin in human and veterinary therapeutics, in a population endemic with nalidixic acid-resistant strains. At present treatment of ciprofloxacin-resistant enteric fever has narrowed down to third and fourth generation cephalosporins, azithromycin, tigecycline and penems.

In addition to the  Problem of Antibiotic Resistance, the Pharma industry is not motivated to renew research efforts for developing newer antibiotic due to lack of Economic Incentives which is a cause of concern.

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted